I’m curious why the drug development isn’t classified as intangibles. Surely development costs should be capitalised.. am I missing something here with generics portfolio. If that’s the case.. the balance sheet is significantly under capitalised
Ann: Appendix 4D and Half Year Financial Report, page-9
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.73M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 152642 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 04/09/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable